CRC CEO Chairs ASCP 2026 Panel on Preventable Failure Risk in CNS Clinical Trials
核心洞察
A panel at the ASCP 2026 Annual Meeting examined how cumulative operational and methodological pressures drive preventable failures in CNS clinical trials.
Panelists emphasized that trial failures often stem from multiple factors—including enrollment quality, rater oversight, and placebo response—rather than a single operational issue.
Approaches to strengthen interpretability include deliberate enrollment strategies, structured rater qualification, operational consistency, and cross-functional alignment during study planning.
Cognitive Research Corporation (搜索) (CRC) Chief Executive Officer Tom Zoda, Ph.D., chaired a panel discussion at the 2026 American Society of Clinical Psychopharmacology (搜索) (ASCP) Annual Meeting focused on common drivers of preventable failure risk in central nervous system (CNS) clinical trials. The 90-minute session, titled "Speed Kills: Why CNS Clinical Trials Fail and How to Protect Signal, Patients, and Programs," convened on Tuesday, May 26, in Miami Beach, Florida.
The panel brought together sponsor, investigator, endpoint quality, and operational perspectives to explore how factors such as enrollment quality, rater qualification and oversight, operational complexity, and study execution challenges can interfere with the ability of CNS trials to reliably distinguish true treatment effects. Joining the discussion were Stephen Brannan, M.D., David Walling, Ph.D., Patrick Harrington, Ph.D., and discussant Alexandria Wise, Ph.D.
Cumulative Pressures, Not Single Failures
Throughout the discussion, panelists emphasized that many CNS trial failures are not attributable to a single operational issue. Rather, they result from cumulative factors that can increase noise, narrow drug-placebo separation, and complicate interpretation in indications already vulnerable to heterogeneous clinical presentation and subjective endpoints. The panel addressed topics including placebo response, endpoint quality, enrollment strategy, operational alignment, and the cumulative operational and methodological pressures that can complicate interpretation in CNS studies.
"The discussion reinforced how sensitive CNS trials are to operational and methodological pressures that can compromise interpretability," said Zoda. "Protecting signal integrity requires thoughtful alignment between scientific intent, operational execution, endpoint quality, and realistic development expectations from the earliest stages of study planning."
Strategies to Strengthen Interpretability
Panelists also discussed approaches organizations are using to strengthen interpretability and reduce preventable variability in CNS studies. These include more deliberate enrollment strategies, structured rater qualification and oversight practices, operational consistency across sites, and stronger cross-functional alignment during study planning and startup.
The ASCP Annual Meeting convenes academic researchers, clinicians, industry leaders, and regulatory experts focused on advancing neuropsychiatric drug development, clinical psychopharmacology, and CNS clinical research. CRC, a neuroscience-specialty contract research organization, supports Phase I–III clinical trials across neurology, psychiatry, and analgesia, with 20 years of exclusive focus on CNS research.